{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:09:08Z","timestamp":1792656548384,"version":"4.5.0"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejphar.2018.07.057","type":"journal-article","created":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T12:13:38Z","timestamp":1533039218000},"page":"61-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"C","title":["Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer"],"prefix":"10.1016","volume":"835","author":[{"given":"Hayley","family":"Heers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Stanislaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Harrelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.07.057_bib1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ajpath.2011.04.042","article-title":"Survivin is a novel target of CD44-promoted breast tumor invasion","volume":"179","author":"Abdraboh","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib2","doi-asserted-by":"crossref","first-page":"R40","DOI":"10.1186\/bcr2327","article-title":"Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours","volume":"11","author":"Albergaria","year":"2009","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib3","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2018.07.057_bib4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/bjc.1989.256","article-title":"Response to endocrine manipulation and oestrogen receptor concentration in large operable primary breast cancer","volume":"60","author":"Anderson","year":"1989","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib5","first-page":"106","article-title":"Tracking and evaluating molecular tumor markers with cancer registry data: HER2 and breast cancer","author":"Anderson","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejphar.2018.07.057_bib6","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s10495-009-0384-0","article-title":"Simultaneous treatment with camptothecin and valproic acid suppresses induction of Bcl-X(L) and promotes apoptosis of MCF-7 breast cancer cells","volume":"14","author":"Arakawa","year":"2009","journal-title":"Apoptosis"},{"key":"10.1016\/j.ejphar.2018.07.057_bib7","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1371\/journal.pone.0000098","article-title":"A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer","volume":"1","author":"Arce","year":"2006","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2018.07.057_bib8","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/dmd.108.022426","article-title":"Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10","volume":"37","author":"Argikar","year":"2009","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejphar.2018.07.057_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bjc.6603851","article-title":"Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial","volume":"97","author":"Atmaca","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1186\/1471-2407-14-875","article-title":"Phase 1\/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial)","volume":"14","author":"Avallone","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib11","first-page":"1107","article-title":"Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade","volume":"58","author":"Baker","year":"2011","journal-title":"Histopathology"},{"key":"10.1016\/j.ejphar.2018.07.057_bib12","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1158\/1078-0432.CCR-11-3165","article-title":"A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors","volume":"18","author":"Banerji","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1146\/annurev-pharmtox-010716-105106","article-title":"Targeting epigenetics in cancer","volume":"58","author":"Bennett","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib14","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1158\/0008-5472.CAN-07-2822","article-title":"Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling","volume":"68","author":"Bicaku","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00280-015-2695-x","article-title":"Phase I trial of valproic acid and lenalidomide in patients with advanced cancer","volume":"75","author":"Bilen","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1055\/s-2004-823026","article-title":"Aromatase and endometriosis","volume":"22","author":"Bulun","year":"2004","journal-title":"Semin. Reprod. Med."},{"key":"10.1016\/j.ejphar.2018.07.057_bib17","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/annonc\/mdm204","article-title":"A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors","volume":"18","author":"Candelaria","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib18","doi-asserted-by":"crossref","first-page":"2930414","DOI":"10.1155\/2016\/2930414","article-title":"Valproic acid, a histone deacetylase inhibitor, in combination with paclitaxel for anaplastic thyroid cancer: results of a multicenter randomized controlled phase II\/III trial","volume":"2016","author":"Catalano","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib19","first-page":"1491","article-title":"Upregulation of NKG2D ligands and enhanced natural killer cell cytotoxicity by hydralazine and valproate","volume":"39","author":"Chavez-Blanco","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-4598-4-22","article-title":"Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study","volume":"4","author":"Chavez-Blanco","year":"2005","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib21","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3892\/ijmm.2015.2263","article-title":"Valproic acid-induced histone acetylation suppresses CYP19 gene expression and inhibits the growth and survival of endometrial stromal cells","volume":"36","author":"Chen","year":"2015","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejphar.2018.07.057_bib22","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1097\/00001813-199711000-00007","article-title":"Sodium valproate inhibits in vivo growth of human neuroblastoma cells","volume":"8","author":"Cinatl","year":"1997","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.ejphar.2018.07.057_bib23","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1038\/srep03456","article-title":"IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1\/2","volume":"3","author":"Cochaud","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2018.07.057_bib24","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2018.07.057_bib25","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/bcr3620","article-title":"Immune approaches to the treatment of breast cancer, around the corner?","volume":"16","author":"Criscitiello","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib26","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1242\/jcs.114.20.3771","article-title":"Gain-of-function of poly(ADP-ribose) polymerase-1 upon cleavage by apoptotic proteases: implications for apoptosis","volume":"114","author":"D'Amours","year":"2001","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.ejphar.2018.07.057_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2008.09.088","article-title":"Valproic acid regulates catecholaminergic pathways by concentration-dependent threshold effects on TH mRNA synthesis and degradation","volume":"1247","author":"D'Souza","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib28","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1158\/1078-0432.CCR-08-1931","article-title":"Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I\/II clinical trial","volume":"15","author":"Daud","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib29","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.drudis.2016.05.012","article-title":"Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer","volume":"21","author":"De Marchi","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2018.07.057_bib30","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/bcr1746","article-title":"Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression","volume":"9","author":"DeNardo","year":"2007","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.2009.23.7370","article-title":"Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer","volume":"28","author":"Denkert","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","article-title":"Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy","volume":"19","author":"Denkert","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/clpt.2011.174","article-title":"Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age","volume":"90","author":"Desta","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2018.07.057_bib34","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1200\/JCO.2009.27.2146","article-title":"Immune regulation of cancer","volume":"28","author":"Disis","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib35","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1158\/1078-0432.CCR-12-1000","article-title":"Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance","volume":"19","author":"Dunbier","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib36","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1189\/jlb.0805448","article-title":"Ischemia-induced angiogenesis: role of inflammatory response mediated by P-selectin","volume":"79","author":"Egami","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jir.2014.0026","article-title":"The role of cytokines in breast cancer development and progression","volume":"35","author":"Esquivel-Velazquez","year":"2015","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib38","first-page":"2782","article-title":"Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation","volume":"61","author":"Evron","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib39","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/ijc.24403","article-title":"Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells","volume":"125","author":"Fazzone","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib40","first-page":"2279","article-title":"Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression","volume":"55","author":"Ferguson","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib41","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.07.057_bib42","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2007.10.006","article-title":"Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells","volume":"259","author":"Fortunati","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejphar.2018.07.057_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.mce.2009.09.011","article-title":"Valproic acid restores ER alpha and antiestrogen sensitivity to ER alpha-negative breast cancer cells","volume":"314","author":"Fortunati","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib44","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.onc.1206113","article-title":"IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells","volume":"22","author":"Freund","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2018.07.057_bib45","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharm. Genom."},{"key":"10.1016\/j.ejphar.2018.07.057_bib46","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ccr.2011.06.004","article-title":"A Pin1\/mutant p53 axis promotes aggressiveness in breast cancer","volume":"20","author":"Girardini","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejphar.2018.07.057_bib47","series-title":"Goodman & Gilman's Pharmacological Basis of Therapeutics","author":"Goodman","year":"2011"},{"key":"10.1016\/j.ejphar.2018.07.057_bib48","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","article-title":"Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells","volume":"20","author":"Gottlicher","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.ejphar.2018.07.057_bib49","first-page":"5195","article-title":"E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas","volume":"55","author":"Graff","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib50","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2018.07.057_bib51","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2013.51.4737","article-title":"Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer","volume":"32","author":"Guarneri","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib52","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0163-7258(02)00299-1","article-title":"Lithium and valproic acid: parallels and contrasts in diverse signaling contexts","volume":"96","author":"Gurvich","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2018.07.057_bib53","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1158\/0008-5472.CAN-03-0799","article-title":"Histone deacetylase is a target of valproic acid-mediated cellular differentiation","volume":"64","author":"Gurvich","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib54","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1158\/0008-5472.CAN-06-4397","article-title":"Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity","volume":"67","author":"Harms","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib55","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.pharmthera.2016.07.014","article-title":"Expanding the view of breast cancer metabolism: promising molecular targets and therapeutic opportunities","volume":"167","author":"Harrelson","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2018.07.057_bib56","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1023\/A:1006141703224","article-title":"The relationship between prognostic and predictive factors in the management of breast cancer","volume":"52","author":"Henderson","year":"1998","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2018.07.057_bib57","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10549-006-9459-6","article-title":"Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells","volume":"105","author":"Hodges-Gallagher","year":"2007","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2018.07.057_bib58","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1507\/endocrj.49.371","article-title":"The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells","volume":"49","author":"Honma","year":"2002","journal-title":"Endocr. J."},{"key":"10.1016\/j.ejphar.2018.07.057_bib59","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.07.057_bib60","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncr.29085","article-title":"Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia","volume":"121","author":"Issa","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib61","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0304-4165(90)90079-C","article-title":"The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase","volume":"1034","author":"Ito","year":"1990","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2018.07.057_bib62","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.molonc.2010.04.002","article-title":"The epigenetics of breast cancer","volume":"4","author":"Jovanovic","year":"2010","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib63","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s10637-015-0262-2","article-title":"First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies","volume":"33","author":"Kim","year":"2015","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ejphar.2018.07.057_bib64","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.tips.2009.09.007","article-title":"HDAC2: a critical factor in health and disease","volume":"30","author":"Kramer","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2018.07.057_bib65","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1093\/emboj\/cdg315","article-title":"The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2","volume":"22","author":"Kramer","year":"2003","journal-title":"EMBO J."},{"key":"10.1016\/j.ejphar.2018.07.057_bib66","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1158\/0008-5472.CAN-05-1663","article-title":"HIN-1, an inhibitor of cell growth, invasion, and AKT activation","volume":"65","author":"Krop","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib67","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S1470-2045(16)00106-6","article-title":"Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Krop","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib68","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-004-1668-2","article-title":"Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis","volume":"90","author":"Krusche","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2018.07.057_bib69","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.4049\/jimmunol.1502024","article-title":"MAGE-C2-specific TCRs combined with epigenetic drug-enhanced antigenicity yield robust and tumor-selective T cell responses","volume":"197","author":"Kunert","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib70","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/path.2866","article-title":"In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival","volume":"224","author":"Ladoire","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib71","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1182\/blood-2006-07-032847","article-title":"Acetylation of GATA-1 is required for chromatin occupancy","volume":"108","author":"Lamonica","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2018.07.057_bib72","doi-asserted-by":"crossref","first-page":"X1","DOI":"10.1530\/ERC-16-0404e","article-title":"The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy","volume":"24","author":"Law","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib73","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1073\/pnas.1008522107","article-title":"Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair","volume":"107","author":"Lee","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2018.07.057_bib74","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1158\/1535-7163.MCT-06-0419","article-title":"Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells","volume":"5","author":"Lee","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejphar.2018.07.057_bib75","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2018.07.057_bib76","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ijc.11724","article-title":"Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays","volume":"109","author":"Lin","year":"2004","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib77","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib78","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/0006-8993(89)91044-5","article-title":"Valproate enhances GABA turnover in the substantia nigra","volume":"501","author":"Loscher","year":"1989","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib79","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1158\/1078-0432.CCR-08-0122","article-title":"A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study","volume":"14","author":"Luu","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib80","doi-asserted-by":"crossref","first-page":"28656","DOI":"10.1074\/jbc.M112.356584","article-title":"The antiepileptic drug valproic acid restores T cell homeostasis and ameliorates pathogenesis of experimental autoimmune encephalomyelitis","volume":"287","author":"Lv","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2018.07.057_bib81","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib82","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.currproblcancer.2016.09.001","article-title":"Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer","volume":"40","author":"Mancuso","year":"2016","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib83","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3892\/or.2016.4988","article-title":"Expression pattern and methylation of estrogen receptor alpha in breast intraductal proliferative lesions","volume":"36","author":"Mao","year":"2016","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejphar.2018.07.057_bib84","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1158\/1535-7163.MCT-05-0194","article-title":"In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates","volume":"4","author":"Marchion","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejphar.2018.07.057_bib85","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1158\/0008-5472.CAN-04-2478","article-title":"Valproic acid alters chromatin structure by regulation of chromatin modulation proteins","volume":"65","author":"Marchion","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib86","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1158\/0008-5472.CAN-05-0064","article-title":"Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer","volume":"65","author":"Martens","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib87","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2013.54.0518","article-title":"Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"32","author":"Mayer","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib88","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1200\/JCO.2008.17.9036","article-title":"FOXP3 expression and overall survival in breast cancer","volume":"27","author":"Merlo","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib89","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1128\/MCB.18.6.3163","article-title":"Increased expression of cyclin D2 during multiple states of growth arrest in primary and established cells","volume":"18","author":"Meyyappan","year":"1998","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib90","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1124\/mol.65.3.520","article-title":"Valproic acid inhibits angiogenesis in vitro and in vivo","volume":"65","author":"Michaelis","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib91","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1200\/JCO.2008.16.8849","article-title":"Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole","volume":"27","author":"Miller","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib92","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib93","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/1471-2407-13-215","article-title":"Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression","volume":"13","author":"Muller","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib94","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/1078-0432.CCR-08-1930","article-title":"Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I\/II trial of valproic acid and epirubicin\/FEC","volume":"15","author":"Munster","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib95","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1200\/JCO.2006.08.6165","article-title":"Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study","volume":"25","author":"Munster","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib96","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1038\/bjc.2011.156","article-title":"A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer","volume":"104","author":"Munster","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib97","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrc2713","article-title":"Biological determinants of endocrine resistance in breast cancer","volume":"9","author":"Musgrove","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib98","first-page":"174","article-title":"Aromatase expression in endometriosis","volume":"81","author":"Noble","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2018.07.057_bib99","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.2353\/ajpath.2007.070535","article-title":"In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver","volume":"171","author":"Ouhtit","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib100","doi-asserted-by":"crossref","first-page":"229ra241","DOI":"10.1126\/scitranslmed.3008326","article-title":"Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer","volume":"6","author":"Pathiraja","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejphar.2018.07.057_bib101","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2018.07.057_bib102","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.radonc.2015.10.009","article-title":"Antiepileptic drug use improves overall survival in breast cancer patients with brain metastases in the setting of whole brain radiotherapy","volume":"117","author":"Reddy","year":"2015","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib103","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1126\/science.3101178","article-title":"Cytochrome P-450--catalyzed formation of delta 4-VPA, a toxic metabolite of valproic acid","volume":"235","author":"Rettie","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2018.07.057_bib104","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1186\/bcr2234","article-title":"T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers","volume":"11","author":"Rody","year":"2009","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molonc.2007.01.001","article-title":"The role of histone deacetylases (HDACs) in human cancer","volume":"1","author":"Ropero","year":"2007","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib106","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1073\/pnas.1104303108","article-title":"Leukocyte composition of human breast cancer","volume":"109","author":"Ruffell","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2018.07.057_bib107","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0022-3565(24)37076-4","article-title":"Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid","volume":"283","author":"Sadeque","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2018.07.057_bib108","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.yexmp.2009.06.003","article-title":"Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis","volume":"87","author":"Saouaf","year":"2009","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib109","doi-asserted-by":"crossref","first-page":"940","DOI":"10.4049\/jimmunol.181.2.940","article-title":"Histone acetylation and flagellin are essential for Legionella pneumophila-induced cytokine expression","volume":"181","author":"Schmeck","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib110","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2018.07.057_bib111","doi-asserted-by":"crossref","first-page":"323","DOI":"10.4048\/jbc.2014.17.4.323","article-title":"Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast","volume":"17","author":"Seo","year":"2014","journal-title":"J. Breast Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib112","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.vph.2014.01.003","article-title":"Epigenetic modulators mitigate angiogenesis through a complex transcriptomic network","volume":"60","author":"Shiva Shankar","year":"2014","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib113","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejphar.2018.07.057_bib114","first-page":"94","article-title":"A genomic approach to predict synergistic combinations for breast cancer treatment","volume":"13","author":"Soldi","year":"2013","journal-title":"Pharm. J."},{"key":"10.1016\/j.ejphar.2018.07.057_bib115","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2407-11-130","article-title":"Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition","volume":"11","author":"Soria","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib116","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/BF01962700","article-title":"Valproate hepatotoxicity syndrome: hypotheses of pathogenesis","volume":"14","author":"Stephens","year":"1992","journal-title":"Pharm. Weekbl. Sci."},{"key":"10.1016\/j.ejphar.2018.07.057_bib117","doi-asserted-by":"crossref","first-page":"e40466","DOI":"10.1371\/journal.pone.0040466","article-title":"Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer","volume":"7","author":"Stone","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2018.07.057_bib118","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2174\/1871520614666140919095828","article-title":"Histone deacetylase inhibitors and colorectal cancer: what is new?","volume":"14","author":"Tampakis","year":"2014","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.ejphar.2018.07.057_bib119","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","article-title":"The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients","volume":"112","author":"Tan","year":"2010","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.ejphar.2018.07.057_bib120","doi-asserted-by":"crossref","first-page":"10373","DOI":"10.18632\/oncotarget.7219","article-title":"Estrogen receptor beta as a prognostic factor in breast cancer patients: a systematic review and meta-analysis","volume":"7","author":"Tan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2018.07.057_bib121","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.clbc.2015.11.003","article-title":"Phase I study of panobinostat (LBH589) and letrozole in postmenopausal metastatic breast cancer patients","volume":"16","author":"Tan","year":"2016","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib122","first-page":"7","article-title":"Variation in CYP2A6 Activity and Personalized Medicine","author":"Tanner","year":"2017","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.ejphar.2018.07.057_bib123","doi-asserted-by":"crossref","first-page":"7715","DOI":"10.18632\/oncotarget.6802","article-title":"Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression","volume":"7","author":"Terranova-Barberio","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejphar.2018.07.057_bib124","first-page":"8948","article-title":"Induction of PIG3 and NOXA through acetylation of p53 at 320 and 373 lysine residues as a mechanism for apoptotic cell death by histone deacetylase inhibitors","volume":"63","author":"Terui","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.dnarep.2017.08.002","article-title":"Valproic acid sensitizes breast cancer cells to hydroxyurea through inhibiting RPA2 hyperphosphorylation-mediated DNA repair pathway","volume":"58","author":"Tian","year":"2017","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejphar.2018.07.057_bib126","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.biocel.2008.08.019","article-title":"Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status","volume":"41","author":"Travaglini","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib127","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/02688697.2011.638996","article-title":"Effect of valproic acid on the outcome of glioblastoma multiforme","volume":"26","author":"Tsai","year":"2012","journal-title":"Br. J. Neurosurg."},{"key":"10.1016\/j.ejphar.2018.07.057_bib128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/onc.2009.334","article-title":"Histone deacetylases and the immunological network: implications in cancer and inflammation","volume":"29","author":"Villagra","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2018.07.057_bib129","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/mol.109.056523","article-title":"Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms","volume":"76","author":"Walker","year":"2009","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib130","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc2809","article-title":"Eicosanoids and cancer","volume":"10","author":"Wang","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib131","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/intimm\/dxn143","article-title":"The transcription repressor, ZEB1, cooperates with CtBP2 and HDAC1 to suppress IL-2 gene activation in T cells","volume":"21","author":"Wang","year":"2009","journal-title":"Int. Immunol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib132","doi-asserted-by":"crossref","first-page":"e0143013","DOI":"10.1371\/journal.pone.0143013","article-title":"Assessment of interactions between cisplatin and two histone deacetylase inhibitors in MCF7, T47D and MDA-MB-231 human breast cancer cell lines - an isobolographic analysis","volume":"10","author":"Wawruszak","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2018.07.057_bib133","first-page":"3472","article-title":"Transcriptional control of estrogen receptor in estrogen receptor-negative breast carcinoma","volume":"53","author":"Weigel","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib134","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12013-011-9276-3","article-title":"Expression of Th17 cells in breast cancer tissue and its association with clinical parameters","volume":"62","author":"Yang","year":"2012","journal-title":"Cell Biochem. Biophys."},{"key":"10.1016\/j.ejphar.2018.07.057_bib135","first-page":"7025","article-title":"Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells","volume":"61","author":"Yang","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib136","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","volume":"31","author":"Yardley","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2018.07.057_bib137","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1186\/bcr2753","article-title":"A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer","volume":"12","author":"Yau","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejphar.2018.07.057_bib138","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1038\/bjc.2016.125","article-title":"Vorinostat in combination with capecitabine plus cisplatin as a first-line chemotherapy for patients with metastatic or unresectable gastric cancer: phase II study and biomarker analysis","volume":"114","author":"Yoo","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejphar.2018.07.057_bib139","doi-asserted-by":"crossref","first-page":"651","DOI":"10.7150\/ijbs.7.651","article-title":"Dual roles of immune cells and their factors in cancer development and progression","volume":"7","author":"Zamarron","year":"2011","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejphar.2018.07.057_bib140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11010-011-1085-x","article-title":"VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin","volume":"361","author":"Zhang","year":"2012","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.ejphar.2018.07.057_bib141","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s10549-005-6001-1","article-title":"Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast*","volume":"94","author":"Zhang","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejphar.2018.07.057_bib142","doi-asserted-by":"crossref","first-page":"6962","DOI":"10.1158\/1078-0432.CCR-04-0455","article-title":"HDAC6 expression is correlated with better survival in breast cancer","volume":"10","author":"Zhang","year":"2004","journal-title":"Clin. Cancer Res."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918304308?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918304308?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T22:24:18Z","timestamp":1757975058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918304308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":142,"alternative-id":["S0014299918304308"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.07.057","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.07.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}